Related Experiment Video
Updated: Jun 17, 2026
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report
Suiting Ao1,2, Mingjia Hu1,2, Fanli Xu1,2
1Dermatology Hospital of Shandong First Medical University, China.
Aim:
To describe the clinical response to the JAK inhibition, upadacitinib, in a patient with cutaneous infectious granulomatosis.
Methods:
We reported a 36-year-old female with chronic, treatment-resistant facial and leg plaques. Histopathology supported a diagnosis of infectious granuloma, but no exact pathogen was detected after antifungal therapy. Immunohistochemical analysis indicated elevated levels of cytokines. This patient was treated with upadacitinib 15 mg daily.
Results:
The symptoms had worsened despite prior antifungal therapy. This patient experienced rapid improvement and sustained remission following treatment with upadacitinib for pathogen-negative, immune-mediated granulomatosis. No recurrences were observed at the 8-month follow-up.
Conclusion:
This case-report highlights a potential role for JAK inhibition, upadacitinib, in managing refractory cutaneous granulomatosis with an excessive immune response despite no identifiable pathogen and pathogen clearance.
